<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201005048927N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-04-27</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of probiotic supplements on uremic pruritus in patients undergoing hemodialysis.</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of Streptococcus thermophilus, Lactiplantibacillus plantarum and the combination of these two probiotics on uremic pruritus in patients undergoing hemodialysis : A double-blind randomized clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-03-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/82905</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Initially, block randomization will be conducted. Grouping of patients will be carried out in a double-blind manner. The drugs and placebo will be provided to the dialysis unit nurse in similar packaging (labeled with numbers one to four) based on block randomization, and they will not be aware of the contents of the packages. Based on the numbers and the patient list, they will distribute the drugs and placebo among the patients, who will also be unaware of the contents of the packages. On the other hand, data collection will be performed by another researcher who has not been involved in the patient allocation process from the beginning and is unaware of it, Blinding description: Participants (the form of the drug in the control group and the three intervention groups are selected to be completely identical in terms of appearance and method of consumption), nurses in the dialysis unit who distribute the medication, a researcher who completes the questionnaires, a researcher who collects data related to patients such as information related to the dialysis records of patients, a researcher who conducts the tests.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: chronic kidney disease. Condition 2: uremic pruritus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:Lactiplantibacillus plantarum group: Oral medication in the form of drops equivalent to CFU=1*109 of Lactiplantibacillus plantarum bacteria administered daily for 12 weeks.Probiotics are prepared by Pardis Roshd Company under the supervision of a food industry specialist. Intervention 2: Intervention group: Thermophilous Streptococcus group: Oral medication in the form of drops equivalent to CFU=1*109 of Thermophilous Streptococcus bacteria administered daily for 12 weeks. Probiotics are prepared by Pardis Roshd Company under the supervision of a food industry specialist. Intervention 3: Intervention group:Oral medication in the form of drops equivalent to CFU=28 109 evenly from Lactiplantibacillus plantarum and Thermophilous Streptococcus bacteria administered daily for 12 weeks. Probiotics are prepared by Pardis Roshd Company under the supervision of a food industry specialist. Intervention 4: Control group: Oral medication in the form of drops (placebo) with maltodextrin administered daily for 12 weeks. Prepared by Pardis Roshd Company under the supervision of a food industry specialist.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahboobe Rastgoo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.243, Substreet 26.3, West Saheli, Shiraz.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7143618995</zip>
        <telephone>+98 71 3225 3578</telephone>
        <email>mahboob.rastgoo@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahboobe Rastgoo</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.243, Substreet 26.3, West Saheli, Shiraz.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7143618995</zip>
        <telephone>+98 71 3225 3578</telephone>
        <email>mahboob.rastgoo@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years
Continuous hemodialysis for more than three months
They should have suffered from itching for at least 6 weeks.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Liver disease
History of seizures
Skin disease associated with itching
Hemolytic blood disease
First complaint of itching
Use of any type of antibiotic
Participation in another clinical trial in the past month
pregnancy
active cancer
Active infection
Sensitivity to probiotic compounds</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18</hc_code>
      <hc_code>L29.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic kidney disease (CKD)</hc_keyword>
      <hc_keyword>Pruritus, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Lactiplantibacillus plantarum group: Oral medication in the form of drops equivalent to CFU=1*109 of Lactiplantibacillus plantarum bacteria administered daily for 12 weeks.Probiotics are prepared by Pardis Roshd Company under the supervision of a food industry specialist.</i_keyword>
      <i_keyword>Intervention group: Thermophilous Streptococcus group: Oral medication in the form of drops equivalent to CFU=1*109 of Thermophilous Streptococcus bacteria administered daily for 12 weeks. Probiotics are prepared by Pardis Roshd Company under the supervision of a food industry specialist.</i_keyword>
      <i_keyword>Intervention group:Oral medication in the form of drops equivalent to CFU=28 109 evenly from Lactiplantibacillus plantarum and Thermophilous Streptococcus bacteria administered daily for 12 weeks. Probiotics are prepared by Pardis Roshd Company under the supervision of a food industry specialist.</i_keyword>
      <i_keyword>Control group: Oral medication in the form of drops (placebo) with maltodextrin administered daily for 12 weeks. Prepared by Pardis Roshd Company under the supervision of a food industry specialist.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Uremic pruritus( method of Scale Analogue Visual and the Persian version of the 5-Scale Itching Questionnaire). Timepoint: At the beginning of the study (before the intervention starts), during the intervention (6 weeks after the intervention starts), and after the intervention (immediately after 12 weeks from the start of the intervention). Method of measurement: To assess itching, the Scale Analogue Visual method and the Persian version of the 5-Scale Itching Questionnaire, whose validity and reliability have been confirmed by Yousef Nejad, will be used.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>C-REACTIVE PROTEIN. Timepoint: At the beginning of the study (before the intervention starts) and at the end of the intervention (after completing 12 weeks). Method of measurement: ELISA.</sec_outcome>
      <sec_outcome>Interlukine-6. Timepoint: At the beginning of the study (before the intervention starts) and at the end of the intervention (after completing 12 weeks). Method of measurement: ELISA.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-03-15</approval_date>
        <contact_name>Shiraz university of medical science</contact_name>
        <contact_address>Shiraz, Zand Street, opposite Palestine Street, Central Building of Shiraz University of Medical Sciences. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
